Several authors (e.g., [158,159,160,161]) have quoted our work that demonstrates GLS1 protein/activity is increased in aggressive prostate cancer cells (cf., [1]), but neglected to provide the rationale associated with the upregulation of the GTωA pathway in these cells. The gene discussed is GLS; the disease is prostate cancer.